Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Tumor type

Renal Cell Carcinoma

OncoTree code RCC · 2 articles

Clinical · Molecular biology

Molecular underpinnings of metastatic small renal masses

Kapur P, Beshnova D, Zhong H, et al.

JCI insight

This study performed integrated morphological and molecular profiling, including whole-exome sequencing and RNA-Seq, on a multiinstitutional cohort of metastatic small renal masses (SRMs). The aim was to understand the molecular underpinnings of metastatic competence in these tumors, which are often managed with active surveillance. Researchers identified distinct genetic alterations in metastatic non-clear cell SRMs, such as NF2-altered tumors, ELOC-mutated RCC, and an mTOR-driven eosinophilic vacuolated tumor. Metastatic clear cell SRMs exhibited multi-hit aggressive genotypes, including recurrent losses of chromosomes 8p, 9, and 14q, along with co-occurring driver alterations in genes like BAP1 and mTOR pathway genes. Transcriptomic analyses revealed an enrichment of the NMF3 subtype, metabolic rewiring, and reduced cytotoxic immune effector function.

Clinical

Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study

Motzer RJ, Albiges L, Treviño Aguirre SA, et al.

Annals of oncology

The phase III COSMIC-313 study investigated the addition of cabozantinib to nivolumab and ipilimumab in previously untreated patients with advanced renal cell carcinoma. Final results confirmed a significant progression-free survival (PFS) benefit for the triplet regimen (16.6 months vs 11.2 months for the doublet). However, no significant improvement in overall survival (OS) was observed. Exploratory biomarker analyses suggest that patients with higher levels of M2-like macrophages might experience improved PFS and OS with the triplet therapy.